Trial Profile
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Emavusertib (Primary) ; Ibrutinib (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms TakeAim Lymphoma
- Sponsors Curis
- 08 Feb 2024 According to a Curis media release, company working open additional clinical sites in the US and Europe for both the TakeAim Leukemia and Lymphoma studies.
- 08 Feb 2024 According to a Curis media release, updated clinical data from the on-going combination study of emavusertib with ibrutinib in the second half of 2024.
- 12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition